UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Current medical research and opinion, 2010-06, Vol.26 (6), p.1519-1530

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD2-07: Alpelisib + letrozole in patients with PIK3CA- mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD2-07-PD2-07

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA -mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD13-05-PD13-05

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) from BYLieve

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-08

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD15-01-PD15-01

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA -mutated advanced breast cancer (ABC) from BYLieve

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1060-1060

2021

Link zum Volltext

Verfügbarkeit prüfen

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2 − ) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1010-1010

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure

Current medical research and opinion, 2011-07, Vol.27 (7), p.1339-1346

2011

Link zum Volltext

Verfügbarkeit prüfen

Molting Mania

Science and children, 2006-04, Vol.43 (7), p.28-31

Arce, Christina

2006

Link zum Volltext

Verfügbarkeit prüfen

The NanoFlow Repository

Bioinformatics (Oxford, England), 2023-06, Vol.39 (6)

2023

Link zum Volltext

Verfügbarkeit prüfen

Social exclusion, neoliberalism and resistance: The role of social workers in implementing social policies in Chile

Critical social policy, 2019-02, Vol.39 (1), p.127-146

2019

Link zum Volltext

Verfügbarkeit prüfen

Role of dendritic cell‐mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw

The FASEB journal, 2020-02, Vol.34 (2), p.2595-2608

2020

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data

Journal of clinical oncology, 2015-02, Vol.33 (6), p.567-574

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficient tRNA degradation and quantification in Escherichia coli cell extract using RNase‐coated magnetic beads: A key step toward codon emancipation

Biotechnology progress, 2017-09, Vol.33 (5), p.1401-1407

2017

Link zum Volltext

Verfügbarkeit prüfen

FISH analysis for chromosomes 13, 16, 18, 21, 22, X and Y in all blastomeres of IVF pre‐embryos from 144 randomly selected donated human oocytes and impact on pre‐embryo morphology

Human reproduction (Oxford), 2003-12, Vol.18 (12), p.2575-2581

2003

Link zum Volltext

Verfügbarkeit prüfen

Racial-ethnic disparities in management and outcomes among children with type 1 diabetes

Pediatrics (Evanston), 2015-03, Vol.135 (3), p.424

2015

Link zum Volltext

Verfügbarkeit prüfen

The T1D Exchange Clinic Registry

The journal of clinical endocrinology and metabolism, 2012-12, Vol.97 (12), p.4383-4389

2012

Link zum Volltext

Verfügbarkeit prüfen

Ethics of DNA research on human remains: five globally applicable guidelines

Nature (London), 2021-11, Vol.599 (7883), p.41-46

2021

Link zum Volltext

Verfügbarkeit prüfen

Successful reconstruction of whole mitochondrial genomes from ancient Central America and Mexico

Scientific reports, 2017-12, Vol.7 (1), p.18100-18100, Article 18100

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)
Buchkapitel
(1)

Sprache

Englisch
(49)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(27)
Humans
(21)
Female
(18)
Male
(15)
Aged
(12)
Middle Aged
(12)
Adult
(10)
Biological And Medical Sciences
(8)
Adolescent
(6)
Aged, 80 And Over
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Animals
(5)
Aneuploidy
(4)
Cells, Cultured
(4)
Medical Sciences
(4)
Obstetrics & Gynecology
(4)
Registries
(4)
Reproductive Biology
(4)
United States
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA -mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA -mutated advanced breast cancer (ABC) from BYLieve

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2 − ) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study

Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure

Molting Mania

The NanoFlow Repository

Social exclusion, neoliberalism and resistance: The role of social workers in implementing social policies in Chile

Role of dendritic cell‐mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data

Efficient tRNA degradation and quantification in Escherichia coli cell extract using RNase‐coated magnetic beads: A key step toward codon emancipation

FISH analysis for chromosomes 13, 16, 18, 21, 22, X and Y in all blastomeres of IVF pre‐embryos from 144 randomly selected donated human oocytes and impact on pre‐embryo morphology

Racial-ethnic disparities in management and outcomes among children with type 1 diabetes

The T1D Exchange Clinic Registry

Ethics of DNA research on human remains: five globally applicable guidelines

Successful reconstruction of whole mitochondrial genomes from ancient Central America and Mexico

Suchergebnisse filtern